tiprankstipranks
Cerus Corp (CERS)
NASDAQ:CERS

Cerus Stock Analysis & Ratings

CERS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.35 - $8.06
Previous Close$5.34
Volume1.01M
Average Volume (3M)1.93M
Market CapN/A
Enterprise ValueN/A
P/E Ratio-18.7
Beta1.52
Next EarningsAug 04, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score9


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

CERS FAQ

What was Cerus’s price range in the past 12 months?
Cerus lowest stock price was $4.34 and its highest was $8.05 in the past 12 months.
    What is Cerus’s market cap?
    Currently, no data Available
    What is Cerus’s price target?
    The average price target for Cerus is $9.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $10.00 ,the lowest forecast is $8.00. The average price target represents 68.54% Increase from the current price of $5.34.
      What do analysts say about Cerus?
      Cerus’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is Cerus’s upcoming earnings report date?
        Cerus’s upcoming earnings report date is Aug 04, 2022 which is in 35 days.
          How were Cerus’s earnings last quarter?
          Cerus released its earnings results on May 05, 2022. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.012.
            Is Cerus overvalued?
            According to Wall Street analysts Cerus’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Cerus pay dividends?
              Cerus does not currently pay dividends.
              What is Cerus’s EPS estimate?
              Cerus’s EPS estimate is -$0.07.
                How many shares outstanding does Cerus have?
                Cerus has 176,898,220 shares outstanding.
                  What happened to Cerus’s price movement after its last earnings report?
                  Cerus reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went up 10%.
                    Which hedge fund is a major shareholder of Cerus?
                    Among the largest hedge funds holding Cerus’s share is ARK Investment Management LLC. It holds Cerus’s shares valued at 89M.

                      ---

                      Cerus Stock Analysis

                      Smart Score
                      9
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $9.00
                      ▲(68.54% Upside)
                      Moderate Buy
                      The Cerus stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cerus Corp

                      Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Haemonetics
                      Cytosorbents
                      Chinook Therapeutics
                      International Stem Cell
                      Aethlon Medical

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis